Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer
Abstract Objective To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab. Methods We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointes...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Cancer Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cnr2.1952 |
| _version_ | 1797292571509129216 |
|---|---|
| author | Kunpeng Fang Jie Wang Jianyong Yuan Chengjun Sui Jiajun Zhi Yong Xia Minmin Sun |
| author_facet | Kunpeng Fang Jie Wang Jianyong Yuan Chengjun Sui Jiajun Zhi Yong Xia Minmin Sun |
| author_sort | Kunpeng Fang |
| collection | DOAJ |
| description | Abstract Objective To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab. Methods We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointestinal perforation. Three patients occurred intestinal perforation after receiving bevacizumab. We analyzed the clinical characteristics of three patients with intestinal perforation. Results All patients receiving bevacizumab. Three of 217 patients occurred intestinal perforation after receiving bevacizumab. Patient no. 1 was 70 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Patient no. 2 was 59 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation after receiving bevacizumab, and recovered smoothly after symptomatic treatment. Patient no. 3 was 60 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Conclusions Patients with advanced colorectal cancer receiving bevacizumab are at risk of gastrointestinal perforation. The patient's age, gender and history of bowel obstruction may be associated with gastrointestinal perforation. |
| first_indexed | 2024-03-07T19:58:23Z |
| format | Article |
| id | doaj.art-c4335acdd0e64806aa1c018fdbeccf76 |
| institution | Directory Open Access Journal |
| issn | 2573-8348 |
| language | English |
| last_indexed | 2024-03-07T19:58:23Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Reports |
| spelling | doaj.art-c4335acdd0e64806aa1c018fdbeccf762024-02-28T13:54:58ZengWileyCancer Reports2573-83482024-02-0172n/an/a10.1002/cnr2.1952Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancerKunpeng Fang0Jie Wang1Jianyong Yuan2Chengjun Sui3Jiajun Zhi4Yong Xia5Minmin Sun6Department of Special Treatment I Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai ChinaDepartment of Hepatic Surgery II Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai ChinaHepatobiliary Pancreatic Surgery, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine Shanghai ChinaDepartment of Special Treatment I Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai ChinaDepartment of Colorectal and Anal Surgery Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai ChinaDepartment of Hepatic Surgery IV Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai ChinaDepartment of Hepatic Surgery I Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) Shanghai ChinaAbstract Objective To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab. Methods We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointestinal perforation. Three patients occurred intestinal perforation after receiving bevacizumab. We analyzed the clinical characteristics of three patients with intestinal perforation. Results All patients receiving bevacizumab. Three of 217 patients occurred intestinal perforation after receiving bevacizumab. Patient no. 1 was 70 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Patient no. 2 was 59 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation after receiving bevacizumab, and recovered smoothly after symptomatic treatment. Patient no. 3 was 60 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Conclusions Patients with advanced colorectal cancer receiving bevacizumab are at risk of gastrointestinal perforation. The patient's age, gender and history of bowel obstruction may be associated with gastrointestinal perforation.https://doi.org/10.1002/cnr2.1952adverse reactionsbevacizumabcolorectal cancergastrointestinal perforation |
| spellingShingle | Kunpeng Fang Jie Wang Jianyong Yuan Chengjun Sui Jiajun Zhi Yong Xia Minmin Sun Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer Cancer Reports adverse reactions bevacizumab colorectal cancer gastrointestinal perforation |
| title | Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer |
| title_full | Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer |
| title_fullStr | Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer |
| title_full_unstemmed | Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer |
| title_short | Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer |
| title_sort | gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer |
| topic | adverse reactions bevacizumab colorectal cancer gastrointestinal perforation |
| url | https://doi.org/10.1002/cnr2.1952 |
| work_keys_str_mv | AT kunpengfang gastrointestinalperforationassociatedwithbevacizumabinmetastaticcolorectalcancer AT jiewang gastrointestinalperforationassociatedwithbevacizumabinmetastaticcolorectalcancer AT jianyongyuan gastrointestinalperforationassociatedwithbevacizumabinmetastaticcolorectalcancer AT chengjunsui gastrointestinalperforationassociatedwithbevacizumabinmetastaticcolorectalcancer AT jiajunzhi gastrointestinalperforationassociatedwithbevacizumabinmetastaticcolorectalcancer AT yongxia gastrointestinalperforationassociatedwithbevacizumabinmetastaticcolorectalcancer AT minminsun gastrointestinalperforationassociatedwithbevacizumabinmetastaticcolorectalcancer |